Effects of Acute L-NMMA Treatment on Renal Hemodynamics and Vasoactive Hormones in Patients With Congestive Heart Failure

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study tests the hypothesis that nitric oxide availability is changed in congestive heart failure with regard to the regulation of renal hemodynamics, renal sodium excretion and release of vasoactive hormones. The study tests these hypotheses by comparing the effects of systemic nitric oxide inhibition with L-NMMA in congestive heart failure patients with healthy subjects on renal hemodynamics, blood pressure and plasma levels of vasoactive hormones.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of the study is to investigate the effects of systemic treatment with Ng-monomethyl-l-arginine in congestive heart failure and healthy controls on:

* glomerular filtration rate and renal plasma flow
* blood pressure and heart rate
* plasma levels of vasoactive hormones
* lithium clearance

The study is randomized and placebo controlled

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Congestive Heart Failure

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Nitric oxide Renal hemodynamics

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Blinding Strategy

SINGLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ng-monomethyl-L-arginine (drug)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Healthy controls

* Age 20 to 60 years
* Both men and women
* Weight below 100 kg
* Normal clinical examination and laboratory screening
* Fertile women only if using contraception
* Informed consent according to the regulations of the local ethics committee

Heart failure

* Both men and women
* Age 20 to 75 years
* Patients with heart failure in NYHA group II-III. Heart failure must be derived from ischaemic heart disease or dilated cardiomyopathy. Diagnosis must be verified by history and echocardiography or isotope cardiography.
* ejection fraction \< 0.40
* P-creatinin \< 250 µmol/L
* Fertile women only if using contraception
* Informed consent according to the regulations of the local ethics committee

Exclusion Criteria

Healthy controls

* History or clinical evidence of diseases of the heart and blood vessels, kidneys, liver and pancreas, endocrine organs, lungs, neoplastic disease, myocardial infarction or cerebrovascular insult as evaluated by clinical examination and laboratory screening
* Current medication
* Drugs or alcohol abuse
* Pregnancy
* Previously within one year received more than 0.2 mSV radioactive treatment or diagnostic substances
* Donation of blood less than 1 month before the experiments

Heart failure

* Cardiac valvular disease with stenosis
* Significant cardiac arrythmia
* Myocardial infarction, PTCA or by-pass surgery less than 3 months before the study
* Diseases of the lever, kidneys, lungs or endocrine organs which are not secondary to congestive heart failure
* Arterial hypertension
* Neoplastic disease
* Cerebrovascular insult
* Treatment with ACE-inhibitors or nitrates which cannot be stopped 1 week before study

Minimum Eligible Age

20 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jesper N Bech, MD, Ph.D.

Role: PRINCIPAL_INVESTIGATOR

Dept. of Medicine, Holstebro Hospital, 7500 Holstebro, Denmark

Erling B Pedersen, Professor

Role: STUDY_CHAIR